Two hands shaking with heart above icon

Refer early to help halt the progression of SCD.1-5

Every VOE contributes to irreversible organ damage, narrowing the therapeutic window for meaningful intervention.1,2,4 Referring earlier is how you interrupt the cycle of VOEs before organ damage accumulates.2,3,5

You don’t need to manage gene therapy, just recognize when it’s time to act. Timely referral can open the door to transformative treatment.1,4,5

People connected by an upward-trending bar chart icon

A referral isn't a handoff—it's a clinical escalation.

Referring for gene therapy with LYFGENIATM helps patients access specialized evaluation while preserving continuity of care.

 

Rethink patient eligibility. Reimagine what’s possible with LYFGENIA.

Not just for the most severe—LYFGENIA may be right for more patients than you think.

The impact of SCD is not one-size-fits-all. VOEs can vary in frequency and severity, but even patients with fewer VOEs can experience long-term organ damage and disruptions to their lives.6,7

LYFGENIA is a gene addition therapy with the potential to decrease or stop VOEs.8

When considering treatment, expand how you see eligibility:

Smaller patient next to taller patient icon

Younger patients (≥ 12 years of age) who may benefit from earlier intervention to help prevent cumulative organ damage2,3,5,8; older patients are eligible as well and have already been successfully enrolled9

Hospital building icon

Those experiencing fewer VOEs can still mean hospitalizations, school/work interruptions, and long-term health risks6,7

Patient chart icon

History of inadequate response to disease-modifying therapies (DMTs) such as hydroxyurea or dependence on chronic transfusion therapy8,10,11

Bar chart with downward arrow icon

Individuals looking to lessen the impact of their VOEs, including crises, and pursue what matters most in their lives8

Person with arms raised icon

Those seeking a different future, defined less by unpredictable VOEs and more by control8

Identifying Patients for Treatment with LYFGENIA

A peer-to-peer discussion of key considerations for identifying patients living with SCD who may be appropriate to refer for LYFGENIA

Patient chart icon
Broadening how you identify patients is critical.

Proactive identification can help prevent continued disease burden, rather than reacting after irreversible damage.2,3,5 We can help you get started.

Request a Representative
Rethink the LYFGENIA Patient

Confidently identify, evaluate, and discuss LYFGENIA with appropriate patients.

Download Patient Eligibility Guide
Could LYFGENIA Be a Part of Your Patient's Next Chapter?

Help patients and caregivers determine their readiness for LYFGENIA and referral for care.

Download Patient Treatment Readiness Tool

Identify patients first. Access can be navigated.

We're here to help. Genetix Biotherapeutics is committed to supporting patient access and coverage throughout the treatment journey.

Coverage approvals have been achieved across multiple payer types, with access pathways being established across commercial and government insurance plans.

Find support that never stops

Shield with check mark icon
Patients continue to gain access to LYFGENIA, with no ultimate denials from payers reported to date.12
 

Shared care can help reduce practice burden.

Qualified Treatment Centers (QTCs) are specialized treatment sites that deliver gene therapy while partnering with referring providers to manage evaluation, coordination, and treatment logistics.

Map pin with plus sign icon

QTCs work in coordination with you to deliver LYFGENIA to your patients.

LYFGENIA QTCs provide the specialized expertise, infrastructure, and multidisciplinary support required for gene therapy. After referral, you may stay informed and involved as part of the continuation of care for your patients.

QTCs follow rigorous quality and oversight standards, which include accreditation by organizations such as the Foundation for the Accreditation of Cellular Therapy (FACT).

Find a Qualified Treatment Center
 

Not sure how to get started?

Your representative can help connect you with a QTC and support next steps in the referral process.

Patient chart icon

Help patients prepare for their first appointment with the QTC team: Patient Treatment Readiness Tool

 

Confirm the right patients and prepare them to move forward.

Identifying potential patients is the first step. From there, evaluating their ability to participate in the treatment journey includes both their clinical and personal readiness.

Clinical considerations

  • Confirm patients meet core clinical eligibility criteria8
  • Consider lifestyle factors that may affect treatment planning
  • Provide education early to support informed consideration of gene therapy from the start

Patient readiness

  • Consider whether patients have support in place for treatment and recovery
  • Assess their ability to manage time away
  • Discuss willingness to undergo conditioning, monitoring, and long-term follow-up8
 

Move from consideration to action with Genetix CARES.

Enroll your patients at no cost to help:

  • Confirm eligibility and identify coverage from the start
  • Access support and resources across the treatment journey
Genetix CARES logo

Support that never stops

Learn More About Genetix CARES

 

Know the moment to act:

When disease control is no longer enough

If your patient continues to experience worsening symptoms or recurrent VOEs despite current therapy, it may be time to consider gene therapy.8,10,11

When today's symptoms signal tomorrow's risk

Ongoing VOEs and disease burden don’t impact just the present; they increase the risk of irreversible organ damage and long-term complications.1,2,13

When SCD begins to limit life

If your patient’s disease is putting their current or future goals at risk, it may be time to explore a different path.14

Talk bubbles icon
Gene therapy conversations don't have to wait.
When disease burden continues to accumulate, earlier action matters.2,3,5

Referral is the first step toward halting the progression of SCD, and it's simple2,3,5:

1 icon

Identify a patient who may benefit

2 icon

Reach out to a Genetix representative

3 icon

Genetix identifies a QTC for referral

From there, Genetix and the QTC guide the process so you and your patient aren't navigating it alone.
Request a Representative
 

Request a Representative

Have questions about eligibility, referrals, or next steps? Please fill out the form below to have a Genetix representative contact you about LYFGENIA.
Back
to Top